In its latest PFDD installment, the FDA offers a detailed roadmap for sponsors seeking to design, adapt, or validate COAs that accurately ...
Immuron Limited announced the submission of the Clinical Study Report for its Phase 2 clinical trial of Travelan® (IMM-124E) to the FDA, which demonstrated statistically significant immunological and ...
View all available purchase options and get full access to this article. Supported by the National Health and Medical Research Council (NHMRC) Postgraduate Scholarship (APP2005294) to N.D.M, Emerging ...
Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a ...
TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative ...
We recently published 10 Stocks Stealing Market Spotlight. Nuvation Bio Inc. (NYSE:NUVB) is one of the best performers on ...
As the curtain closed on 2024, FDA issued a new draft guidance to assist clinical trial sponsors, investigators, and institutional review boards (“IRBs”) with defining, identifying, and reporting ...
SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...
The ABPI is calling on sites to set and meet higher recruitment targets, faster set-up, and executive accountability in NHS ...